EssilorLuxottica's participation in the 2026 Asia-Pacific Academy of Ophthalmology Annual Meeting (APAO 2026) in Hong Kong reinforces its commitment to ophthalmological innovation
Essex Bio-Tech Participates in Hong Kong's 2026 Asia-Pacific Academy of Ophthalmology Congress (APAO 2026) to Strengthen Commitment to Ophthalmology Innovation
Essex Bio-Technology Limited (“Essex Bio-Tech” or “the Group”, stock code:$ESSEX BIO-TECH(1061.HK)) is pleased to announce its successful participation in the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held at the Hong Kong Convention and Exhibition Centre from February 5 to 8, 2026.
This year's APAO Congress brought together approximately 11,000 ophthalmologists and industry professionals from the Asia-Pacific region, providing an excellent platform for Essex Bio-Tech to showcase its core ophthalmology products and R&D pipeline. The Group's team engaged in in-depth exchanges with numerous attendees at the exhibition booth, highlighting the Group's growing influence and steadfast commitment to ophthalmology innovation in the Asia-Pacific region.
Notably, Essex Bio-Tech's poster study, “Anatomical and Patient-Reported Outcomes of Bevacizumab versus Ranibizumab in Wet Age-Related Macular Degeneration: The AURA-1 Study,” was selected for an oral presentation at the congress. Based on Phase III clinical data of the bevacizumab candidate drug (EB12-20145P), the presentation focused on the Group's continued clinical progress in the field of anti-vascular endothelial growth factor (anti-VEGF) therapy for wet age-related macular degeneration (wAMD).
Furthermore, Essex Bio-Tech provided exclusive support for the APAO Young Ophthalmologists (YO) program at this congress, reflecting the Group's philosophy of nurturing future leaders in ophthalmology. Through the EssexBio Academy, the Group is committed to supporting the professional development and knowledge sharing of young talents in this field.
About Essex Bio-Tech (Stock Code:$ESSEX BIO-TECH(1061.HK))
Essex Bio-Tech is a biopharmaceutical company focused on the research, development, production, and sales of the genetically engineered drug b-bFGF. It has six genetically engineered drugs, including Befushu®, Befuji®, and Befuxin®, marketed and sold in China. Additionally, the company possesses a diversified product portfolio including a series of preservative-free single-dose eye drops and Shilishun® Lecithin Iodine Complex Capsules, primarily used for wound healing and disease treatment in the fields of ophthalmology and dermatology prescription drugs. These products are marketed and sold in over 14,100 hospitals with the support of the company's 46 regional offices in China. Leveraging its R&D platforms in growth factors and antibody technology, Essex Bio-Tech has a robust R&D pipeline across multiple clinical stages, covering a wide range of fields and indications.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
